PAXMAN publishes its interim report for Q1 2026

• The Group’s sales amounted to 89.6 (67.1) MSEK for the first quarter of the year of which 18.9 MSEK stems from Dignitana sales.
• EBITDA amounted to 10.5 (10.3) MSEK for the quarter, affected by a positive 5.8 MSEK EBITDA from the Dignitana Group.
• The Group’s net result totalled -0.1 (-5.5) MSEK for the quarter. 5.3 MSEK of costs relates to the acquisition, due to goodwill amortisation.
• The above results lead to an earnings per share of -0.01 (-0.26) SEK for the period.
• The net cash outflow for the period amounted to -15.0 (114) MSEK as a result repayment of financing and working capital movements. In the same quarter last year a cash inflow of 117 MSEK was a result of the direct share issue.
• Cash flow from operating activities amounted to -2.2 (6.2) MSEK for the quarter. A significant factor behind the change compared with the corresponding period last year is the increase in operating receivables.
• Cash on hand totalled 106 (152.7) MSEK at the end of the period.

A live interview with the CEO regarding the interim report will be broadcast here: https://qcnl.tv/p/HyAeq-MqrsguANQC8NPKUw

Significant events during the reporting period

CPT® Category I codes for mechanised scalp cooling became effective from 1st January 2026, widening reimbursement access for patients across the United States. Providers using the former temporary Category III codes will now bill under the Category I codes having determined payment rates within their billing, revenue and medical record systems.

On 20th February 2026, Paxman announced that the American Medical Association (AMA) CPT Editorial Panel has established three CPT® Category III codes describing the use of the Paxman Cryocompression Device for the prevention of chemotherapyinduced peripheral neuropathy (CIPN) in hands and feet. Taking effect January 1, 2027, the new Category III codes establish a standardised reporting pathway for mechanical extremity cryocompression therapy delivered in conjunction with neurotoxic chemotherapy. The three-code structure mirrors the established coding framework for Paxman’s FDAcleared scalp cooling system, supporting structured reporting, data collection, and payer engagement.

Significant events after the reporting period

On 2nd April 2026, West Virginia Governor Patrick Morrisey signed HB 4089 – a scalp cooling legislative bill to mandate insurance coverage for scalp cooling. The bill becomes effective January 1st, 2027.

On 14th April 2026, Maryland Governor Wes Moore signed HB 0393 / SB 0272, enacting a similar scalp cooling bill following an investigative study, which becomes effective January 1st, 2027. Backed by strong patient advocacy, the signing of this bill brings the total number of states with enacted legislation around scalp cooling to four – alongside West Virginia, New York and Louisiana – with 11 more currently pending.